The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor

Yuichi Shibui1, Kenichi Kohashi1, Akihiko Tamaki1

  • 1Department of Anatomic Pathology Graduate School of Medical Sciences, Kyushu University, Maidashi3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan.

Abstract

Insights

Forkhead box transcription factor 1 (FOXM1) is overexpressed in malignancies. Downregulating FOXM1 in malignant rhabdoid tumor (MRT) cells inhibited proliferation and drug resistance, suggesting FOXM1 as a potential therapeutic target for this aggressive sarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Malignant rhabdoid tumor (MRT) is a rare, aggressive sarcoma with poor prognosis.
  • Novel therapeutic strategies are crucial for improving MRT patient outcomes.
  • Forkhead box transcription factor 1 (FOXM1) is implicated in the pathogenesis of various human cancers.

Purpose of the Study:

  • To investigate the clinicopathological and prognostic significance of FOXM1 expression in MRT.
  • To elucidate the role of FOXM1 in MRT progression and its potential as a therapeutic target.

Main Methods:

  • Immunohistochemistry was used to analyze FOXM1 expression in 23 MRT specimens.
  • Clinicopathological and prognostic analyses were performed.
  • Small interfering RNA (siRNA) and a FOXM1 inhibitor (thiostrepton) were used to downregulate FOXM1 in MRT cell lines.
  • In vitro assays assessed the effects of FOXM1 downregulation on cell proliferation, drug resistance, migration, invasion, cell cycle, and apoptosis.
  • cDNA microarray analysis identified FOXM1-regulated genes involved in DNA damage repair.

Main Results:

  • Primary renal MRTs exhibited significantly lower FOXM1 protein expression.
  • Downregulation of FOXM1 in MRT cell lines via siRNA or thiostrepton inhibited cell proliferation, chemoresistance, migration, and invasion.
  • FOXM1 inhibition induced cell cycle arrest and apoptosis in MRT cell lines.
  • FOXM1 was found to regulate FANCD2 and NBS1, key genes in DNA damage repair pathways.

Conclusions:

  • FOXM1 plays a significant role in the progression of malignant rhabdoid tumors.
  • FOXM1 inhibition demonstrates potential for therapeutic intervention in MRT.
  • FOXM1 represents a promising therapeutic target for malignant rhabdoid tumors.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K